Advertisement
Advertisement

VVOS

VVOS logo

Vivos Therapeutics, Inc. Common Stock

0.66
USD
Sponsored
0.00
+0.18%
May 08, 16:00 UTC -4
Closed
exchange

After-Market

0.66

-0.01
-1.32%

VVOS Earnings Reports

Positive Surprise Ratio

VVOS beat 8 of 20 last estimates.

40%

Next Report

In 3 Days
Date of Next Report
May 13, 2026
Estimate for Q1 26 (Revenue/ EPS)
$4.31M
/
-$0.46
Implied change from Q4 25 (Revenue/ EPS)
+12.70%
/
-19.30%
Implied change from Q1 25 (Revenue/ EPS)
+42.89%
/
+2.22%

Vivos Therapeutics, Inc. Common Stock earnings per share and revenue

On Apr 15, 2026, VVOS reported earnings of -0.57 USD per share (EPS) for Q4 25, missing the estimate of -0.49 USD, resulting in a -17.65% surprise. Revenue reached 3.82 million, compared to an expected 6.58 million, with a -41.85% difference. The market reacted with a +8.26% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 4 analysts forecast an EPS of -0.46 USD, with revenue projected to reach 4.31 million USD, implying an decrease of -19.30% EPS, and increase of 12.70% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Quoin Pharmaceuticals, Ltd. - ADR
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.96
Actual
-$1.77
Surprise
+9.93%
logo
ZOETIS INC.
Report Date
May 07, 2026 For Q1 26
Estimate
$1.63
Actual
$1.53
Surprise
-6.19%
logo
Stevanato Group S.p.A.
Report Date
May 07, 2026 For Q1 26
Estimate
$0.10
Actual
$0.11
Surprise
+5.45%
logo
Crinetics Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.26
Actual
-$1.23
Surprise
+2.51%
logo
NewAmsterdam Pharma Company N.V. Ordinary Shares
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.50
Actual
-$0.40
Surprise
+20.32%
logo
Collegium Pharmaceutical, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$1.62
Actual
$1.76
Surprise
+8.43%
logo
Xeris Biopharma Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.00
Actual
$0.01
Surprise
+296.08%
logo
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
May 07, 2026 For Q1 26
Estimate
$0.24
Actual
$0.24
Surprise
-1.96%
logo
SIGA Technologies Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-
Actual
-$0.05
Surprise
-
logo
Profound Medical Corp. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.25
Actual
-$0.19
Surprise
+25.75%
FAQ
For Q4 2025, Vivos Therapeutics, Inc. Common Stock reported EPS of -$0.57, missing estimates by -17.65%, and revenue of $3.82M, -41.85% below expectations.
The stock price moved up 8.26%, changed from $1.09 before the earnings release to $1.18 the day after.
The next earning report is scheduled for May 13, 2026.
Based on 4 analysts, Vivos Therapeutics, Inc. Common Stock is expected to report EPS of -$0.46 and revenue of $4.31M for Q1 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement